Allred DC - Search Results

1

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.

Harvey JM, Clark GM, Osborne CK, Allred DC. Harvey JM, et al. Among authors: allred dc. J Clin Oncol. 2023 Mar 1;41(7):1331-1338. doi: 10.1200/JCO.22.02500. J Clin Oncol. 2023. PMID: 36827742

2

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al. Allred DC, et al. J Clin Oncol. 1992 Apr;10(4):599-605. doi: 10.1200/JCO.1992.10.4.599. J Clin Oncol. 1992. PMID: 1548522 Clinical Trial.

3

Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.

Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK. Ravdin PM, et al. Among authors: allred dc. J Clin Oncol. 1994 Mar;12(3):467-74. doi: 10.1200/JCO.1994.12.3.467. J Clin Oncol. 1994. PMID: 8120545

4

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK. Elledge RM, et al. Among authors: allred dc. J Clin Oncol. 1997 May;15(5):1916-22. doi: 10.1200/JCO.1997.15.5.1916. J Clin Oncol. 1997. PMID: 9164202

5

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK. Elledge RM, et al. Among authors: allred dc. Clin Cancer Res. 1998 Jan;4(1):7-12. Clin Cancer Res. 1998. PMID: 9516946

6

Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Diab SG, et al. Among authors: allred dc. J Clin Oncol. 1999 May;17(5):1442-8. doi: 10.1200/JCO.1999.17.5.1442. J Clin Oncol. 1999. PMID: 10334529

7

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Harvey JM, Clark GM, Osborne CK, Allred DC. Harvey JM, et al. Among authors: allred dc. J Clin Oncol. 1999 May;17(5):1474-81. doi: 10.1200/JCO.1999.17.5.1474. J Clin Oncol. 1999. PMID: 10334533

8

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM. Zellars RC, et al. Among authors: allred dc. J Clin Oncol. 2000 May;18(9):1906-13. doi: 10.1200/JCO.2000.18.9.1906. J Clin Oncol. 2000. PMID: 10784631

9

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Gutierrez MC, et al. Among authors: allred dc. J Clin Oncol. 2005 Apr 10;23(11):2469-76. doi: 10.1200/JCO.2005.01.172. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753463

10

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Allred DC, et al. J Natl Cancer Inst. 1993 Feb 3;85(3):200-6. doi: 10.1093/jnci/85.3.200. J Natl Cancer Inst. 1993. PMID: 8423624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters